Vestibular schwannoma represents a significant clinical challenge characterized by hearing loss, vestibular dysfunction, and cranial nerve morbidity. Despite advancements in surgery and radiotherapy, pharmacological options for recurrent, bilateral, or progressive disease remain limited....
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is a translational review of emerging molecular targets for vestibular schwannoma; none of the therapies discussed have reached standard clinical practice yet.
Identifying mechanism-targeted therapies could eventually offer hearing-preserving alternatives to surgery and radiation for vestibular schwannoma patients.
- 01Review maps emerging molecular pathways driving vestibular schwannoma growth and nerve damage.
- 02Mechanism-targeted (molecular) therapies are explored as alternatives to surgery and radiotherapy.
- 03Tumor causes hearing loss, balance dysfunction, and cranial nerve complications.
- 04Study published in Biomedicine & Pharmacotherapy, focusing on translational (lab-to-clinic) horizons.
- 05No clinical-stage targeted therapy for vestibular schwannoma is currently standard of care.
Emerging molecular pathway-targeted therapies may offer new treatment options for vestibular schwannoma beyond surgery and radiation.
opinionpartially supported- PMID
- 42837724
- DOI
- 10.1016/j.biopha.2026.119975.
- Journal
- Biomedicine & Pharmacotherapy
- Publication type
- review
- Evidence level
- 5
- Population
- Not applicable — narrative review of molecular and translational literature on vestibular schwannoma
- Intervention
- Mechanism-targeted molecular therapies for vestibular schwannoma
Primary outcomes
Identification of molecular pathways implicated in vestibular schwannoma pathogenesis; Evaluation of translational potential of targeted therapies